Nichiiko Sanofi Japan Gets Permission From Sanofi To Sell Anti-Allergy Allegra Generic From June
This article was originally published in PharmAsia News
Nichiiko’s and Sanofi’s joint venture company Nichiiko Sanofi Aventis was given permission to exclusively produce and market SANIK, the generic version of Sanofi’s anti-allergy drug Allegra (fexofenadine hydrochloride) on April 16.
You may also be interested in...
Mallinckrodt’s Terlipressin Narrowly Clears US FDA Panel As Need For Liver Treatment Outweighs Safety Worries
Advisory committee votes 8-7 to recommend approval for terlipressin to treat HRS-1 but is critical of Mallinckrodt’s plan to mitigate the risk of respiratory failure.
ECHA Committee Stops Short Of Advising Derogation Or Deadline Extension For Cosmetic Microplastic Ban
Uncertainties related to leave-on cosmetics’ microplastic releases to the environment, and the costs industry would face in removing microplastic from such products, “do not allow for SEAC to conclude whether other options would be more appropriate than a ban,” the European Chemicals Agency’s Socio-Economic Analysis Committee says in a 1 July draft opinion.
US FDA could revoke orphan designation or exclusivity if cost recovery requirements were not satisfied under bill unanimously passed by the House Energy and Commerce Committee.